Why Catalyst Pharmaceutical Partners (CPRX) Stock Is Spiking Today

NEW YORK (TheStreet) -- Catalyst Pharmaceutical Partners  (CPRX) shares are up 14.2% to $3.41 on Tuesday after ROTH Capital raised the company's price target to $6 from $5 and reiterated its "buy" rating.

The upgraded outlook stems from Catalyst's positive phase III study results of Firdapse, a treatment for Lamber-Eaton Myasthenic Syndrome.

Some analysts believe that this news will lead to a prohibitive price tag of between $60,000 and $80,000 a year for the treatment.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet's Adam Feuerstein discusses the implications of the study results in depth here.

CPRX Chart CPRX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

One Reason Why Catalyst Pharmaceuticals (CPRX) Stock Is Jumping Today

One Reason Why Catalyst Pharmaceuticals (CPRX) Stock Is Jumping Today

These 7 Stocks Under $10 Could Make You a Lot of Money

These 7 Stocks Under $10 Could Make You a Lot of Money

Anavex Plays the Orphan Drug Stock Promotion Game

Anavex Plays the Orphan Drug Stock Promotion Game